MRKR
Closed
Marker Therapeutics Inc
1.51
-0.02 (-1.31%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.53
Day's Range: 1.4801 - 1.55
Send
sign up or login to leave a comment!
When Written:
0.85
Marker Therapeutics Inc. is a clinical-stage immuno-oncology company that develops novel T cell-based immunotherapies for the treatment of various cancers. The company's proprietary MultiTAA technology platform allows for the creation of personalized T cell therapies that target multiple tumor-associated antigens (TAAs) simultaneously, increasing the effectiveness of the therapy. Marker Therapeutics' lead product candidate, MT-401, is a potential treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing other T cell therapies targeting solid tumors such as breast cancer and lung cancer. Marker Therapeutics is headquartered in Houston, Texas, and was founded in 2014.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








